Kuick Research Report Highlights Emerging Role Of Checkpoint Inhibitors in Cancer Therapy With Insight on Ongoing Clinical Trials And Approved Combination Therapies
Kuick Research Report Highlights Emerging Role Of Checkpoint Inhibitors in Cancer Therapy With Insight on Ongoing Clinical Trials And Approved Combination Therapies
With the advancement in the understanding of cancer biology, research is mainly focused on the identification of other targets which can overcome the issue of incomplete tumor regression or relapse following treatment. Further advancement in the field of immune checkpoint therapy and considerable research activities has also led to identification of a few other immune checkpoints which also have potential for anticancer immunotherapy such as lymphocyte activation gene-3 (LAG-3), T-cell membrane protein-3, signal transducer and activator of transcription 3 (STAT3), T cell immunoglobulin and ITIM domain (TIGIT), and glucocorticoid-induced tumor necrosis factor receptor (TNFR) family related protein (GITR). Among all these emerging immune checkpoints, LAG-3 and TIGIT are the most promising in the pipeline.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
Several PD-1/PD-L1 immune checkpoint combinations with CTLA-4 have gained approval by the regulatory bodies for the management of cancer. Indeed, the combination of anti-CTLA-4 with anti-PD-1 treatments showed superior efficacy compared to individual administration. The rational of combining multiple checkpoint inhibitors is that they have different mechanisms of action, with anti – CTLA-4 mainly acting in the lymph node compartment which is responsible for restoring the induction and proliferation of activated T cells, and with anti –PD-1 mainly acting at the periphery of tumor site, preventing the neutralization of cytotoxic T cells by PD-L1 expressing tumor and plasmacytoid dendritic cells in the tumor microenvironment (TME).
In 2018, Keytruda was approved in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Further in 2019, Keytruda in combination with Inlyta (axitinib) was approved for the first-line treatment of patients with advanced renal cell carcinoma (RCC). In the same year, Keytruda plus Lenvima was approved for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
In November 2020, the drug was approved in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer. In 2021, US FDA has approved Keytruda in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. In the same year, Keytruda plus Lenvima was approved for the treatment of patients with advanced renal cell carcinoma.
Moreover, US FDA has also granted approval to Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1. Apart from US, the drug has also been approved in other regions. Keytruda was granted European marketing authorization in 2015. In 2019, Keytruda (pembrolizumab) anti-PD-1 therapy has secured approval in China for first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. In 2020, keytruda was approved in Japan for the second-line treatment of patients with radically unresectable, advanced or recurrent esophageal squamous cell carcinoma whose tumors express PD-L1.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com